Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Vivien Yeo, Michelle Dowsey, Victoria Alguera-Lara, Jemimah Ride, Emily Lancsar & David J. Castle. (2021) Antipsychotic choice: understanding shared decision-making among doctors and patients. Journal of Mental Health 30:1, pages 66-73.
Read now
Read now
Lesia V Tchobaniouk, Erin E McAllister, Danielle L Bishop, Rachel M Carpentier, Katharine R Heins, Robert J Haight & Jeffrey R Bishop. (2019) Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations. Patient Preference and Adherence 13, pages 2233-2241.
Read now
Read now
John FP Bridges, Kathleen Beusterien, Stephan Heres, Pedro Such, Joaquín Sánchez-Covisa, Anna-Greta Nylander, Elcie Chan & Anne de Jong-Laird. (2018) Quantifying the treatment goals of people recently diagnosed with schizophrenia using best–worst scaling. Patient Preference and Adherence 12, pages 63-70.
Read now
Read now
Leslie Citrome. (2017) Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics 17:10, pages 1029-1043.
Read now
Read now
Daniel Eek, Meaghan Krohe, Iyar Mazar, Alison Horsfield, Farrah Pompilus, Rachel Friebe & Alan L Shields. (2016) Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Preference and Adherence 10, pages 1609-1621.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Miguel Bernardo, Luis San, José M Olivares, Tatiana Dilla, Pepa Polavieja, Inmaculada Gilaberte, María Álvarez & Antonio Ciudad. (2011) Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. Patient Preference and Adherence 5, pages 601-610.
Read now
Read now
Articles from other publishers (19)
Emily Groenendaal, Sean Lynch, Rhea Dornbush, Lidia Klepacz & Stephen Ferrando. (2023) Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: A naturalistic cohort study. Journal of Psychiatric Research 158, pages 273-280.
Crossref
Crossref
Justin Faden & Leslie Citrome. (2022) How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia. Clinical Therapeutics 44:4, pages 476-479.
Crossref
Crossref
NageshB Pai & Shae-LeighC Vella. (2022) Strategies for promoting treatment adherence in schizophrenia. Archives of Medicine and Health Sciences 10:1, pages 55.
Crossref
Crossref
Masakazu Hatano, Ippei Takeuchi, Kanade Yamashita, Aoi Morita, Kaori Tozawa, Takashi Sakakibara, Genta Hajitsu, Manako Hanya, Shigeki Yamada, Nakao Iwata & Hiroyuki Kamei. (2021) Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan. Clinical Psychopharmacology and Neuroscience 19:4, pages 610-617.
Crossref
Crossref
Junli Zhu, Yun Chen, Wei Lu, Qingzhi Huang, Bin Li, Ying Xu, Rui Xi & Lefan Jin. (2021) Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities. Frontiers in Public Health 9.
Crossref
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Crossref
Mark Pearson, Tara Sibson & Timothy Carter. (2020) A qualitative study of service users’ experiences of mental health nurses’ knowledge and skills in relation to medication. Journal of Psychiatric and Mental Health Nursing 28:4, pages 682-691.
Crossref
Crossref
Leslie Citrome. (2021) Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums 26:2, pages 118-129.
Crossref
Crossref
Gianluca Fiore, Davide Elia Bertani, Mattia Marchi, Graça Cardoso & Gian Maria Galeazzi. (2021) Patient subjective experience of treatment with long-acting injectable antipsychotics: a systematic review of qualitative studies. Jornal Brasileiro de Psiquiatria 70:1, pages 68-77.
Crossref
Crossref
William Tak‐Lam Lo, Daniel Ki‐Yan Mak, Michael Ming‐Cheuk Wong, Oi‐Wah Chan, Eileena Mo‐Ching Chui, Dicky Wai‐Sau Chung, Glendy Suk‐Han Ip, Ka‐Shing Lau, Che‐Kin Lee, Jolene Mui, Ka‐Lok Tam, Samson Tse & Kwong‐Lui Wong. (2021) Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence. CNS Neuroscience & Therapeutics 27:S1, pages 12-19.
Crossref
Crossref
Sandeep Grover, Swapnajeet Sahoo, Subodh BN, Nidhi Malhotra, Devakshi Dua & Ajit Avasthi. (2019) Attitude and perceptions of patients towards long acting depot injections (LAIs). Asian Journal of Psychiatry 44, pages 200-208.
Crossref
Crossref
Jonathan K. Lai & Howard C. Margolese. (2019) A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Schizophrenia Research 204, pages 443-444.
Crossref
Crossref
Stanley Mutsatsa. (2017) The use of long-acting injectable antipsychotic medication. British Journal of Mental Health Nursing 6:3, pages 114-117.
Crossref
Crossref
Taishiro Kishimoto, Sohag Sanghani, Mark J. Russ, Akeem N. Marsh, Joshua Morris, Suparna Basu, Majnu John & John M. Kane. (2017) Indications for and use of long-acting injectable antipsychotics. International Clinical Psychopharmacology 32:3, pages 161-168.
Crossref
Crossref
Robin Emsley, Koksal Alptekin, Jean-Michel Azorin, Fernando Cañas, Vincent Dubois, Philip Gorwood, Peter M. Haddad, Dieter Naber, José Manuel Olivares, Georgios Papageorgiou, Miguel Roca, Pierre Thomas, Ludger Hargarter & Andreas Schreiner. (2015) Nurses’ perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Therapeutic Advances in Psychopharmacology 5:6, pages 339-350.
Crossref
Crossref
Richard Whale, Marco Pereira, Sharon Cuthbert & Renata Fialho. (2015) Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment. Journal of Clinical Psychopharmacology 35:5, pages 591-595.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Andreas Schreiner, Paul Bergmans, Pierre Cherubin, Sofia Keim, Elmars Rancans, Yasin Bez, Eduard Parellada, Bernardo Carpiniello, Pierre Vidailhet & Ludger Hargarter. (2014) A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. Clinical Therapeutics 36:10, pages 1372-1388.e1.
Crossref
Crossref
Paul Geerts, Guadalupe Martinez & Andreas Schreiner. (2013) Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry 13:1.
Crossref
Crossref